Table of contents
September 2007 Vol 7 No 9
From the editors
p635 | doi:10.1038/nrc2227
Research Highlights
Tumour suppressors: The dark side of p27 | PDF (117 KB)
p637 | doi:10.1038/nrc2216
Breast cancer: A striking resemblance | PDF (581 KB)
p638 | doi:10.1038/nrc2213
Oncogenes: Translocation | PDF (402 KB)
p638 | doi:10.1038/nrc2217
Leukaemia: Xceptional target? | PDF (361 KB)
p639 | doi:10.1038/nrc2214
Therapeutics: Promoting a mixed message | PDF (892 KB)
p640 | doi:10.1038/nrc2218
Trial Watch
Detection of ductal carcinoma | Hazards of sequential kinase inhibitor therapy | PDF (78 KB)
p640 | doi:10.1038/nrc2226
Ageing: Getting old and cancer: hand-in-hand? | PDF (200 KB)
p641 | doi:10.1038/nrc2215
In the news
Western style: a recurring theme? | PDF (76 KB)
p641 | doi:10.1038/nrc2224
Microenvironment: Dependency | PDF (373 KB)
p642 | doi:10.1038/nrc2219
Lung cancer: Expanding the range | PDF (282 KB)
p642 | doi:10.1038/nrc2220
Mouse models: Restricted in time and space | PDF (368 KB)
p642 | doi:10.1038/nrc2221
In brief
Microrna | Prostate cancer | Stem cells | Oncogenes | PDF (92 KB)
p643 | doi:10.1038/nrc2225
Reviews
Maximizing mouse cancer models
Kristopher K. Frese & David A. Tuveson
p654 | doi:10.1038/nrc2192
Animal models of cancer are an immense resource for cancer medicine, but only now are we realising their full potential. What new approaches are needed to derive the maximum value for cancer patients from mouse models of cancer?
Modelling breast cancer: one size does not fit all
Tracy Vargo-Gogola & Jeffrey M. Rosen
p659 | doi:10.1038/nrc2193
Breast cancer is not a single disease, but is instead a collection of diseases that have distinct histopathological features, genetic and genomic variability, and diverse prognostic outcomes. What is the most powerful way to investigate this heterogeneous disease?
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine, Animesh Pardanani, Ayalew Tefferi & D. Gary Gilliland
p673 | doi:10.1038/nrc2210
The myeloproliferative disorders (MPD) polycythaemia vera (PV), essential thombocythaemia (ET), and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic progenitors, and most patients with these diseases acquire a single point mutation in the cytoplasmic tyrosine kinase JAK2 (JAK2V617F). What are the implications of these findings for MPD?
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Kristin K. Deeb, Donald L. Trump & Candace S. Johnson
p684 | doi:10.1038/nrc2196
Accumulating evidence indicates that the active metabolite of vitamin D, 1
,25(OH)2D3, or vitamin D analogues might have potential as anticancer agents because their administration has antiproliferative effects, can activate apoptotic pathways and inhibit angiogenesis. What are the possibilities for 1,25(OH)2D3 and vitamin D analogues as preventative and therapeutic anticancer agents?
Perspectives
Opinion
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Louis M. Weiner
p701 | doi:10.1038/nrc2209
Advances in antibody engineering make it possible to produce various recombinant proteins that exploit the specificity of the antibody- combining site to manipulate tumour-related signalling, and to stimulate anti-tumour immune responses. but can we improve antibodies further to fully engage the tumour immune response?
Opinion
Are oncoantigens suitable targets for anti-tumour therapy?
Federica Cavallo, Raffaele Adolfo Calogero & Guido Forni
p707 | doi:10.1038/nrc2208
This Perspective discusses the feasibility of identifying oncoantigens (proteins required for tumour progression) using mouse models and human mRNA profiling data. Will such oncoantigens make good cancer vaccine targets?
Opinion
Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state
Kelly A. Green & Jason S. Carroll
p713 | doi:10.1038/nrc2211
Oestrogen receptor-a (ERa)-regulated transcription in breast cancer cells involves protein co-factors that contribute to the regulation of chromatin structure. How do these relate with ER activity and potentially with the activity of breast cancer drugs, including tamoxifen?
Correspondence
Correspondence: Pituitary hormone receptors and tumorigenesis
Anat Ben-Shlomo & Shlomo Melmed
| doi:10.1038/nrc2069-c1
